

Figure S1. HPLC chromatograms of the isolated compounds 2-6 and nialamide (1). HPLC, high-performance liquid chromatography; 1 nialamide; 2, nialamionsin; 3,3-amino-*N*-benzylpropanamide; 4,3-methoxy-*N*-benzylpropanamide; 5,3-hydroxy-*N*-benzylpropanamide; 6, *N*-benzylpropanamide.




Figure S2. ^1H NMR spectrum of compound 2 in $\text{DMSO}-d_6$. NMR, nuclear magnetic resonance; 2, nialamionsin; ppm, parts per million.




Figure S3. ^{13}C NMR spectrum of compound 2 in $\text{DMSO}-d_6$. NMR, nuclear magnetic resonance; 2, nialamionsin; ppm, parts per million.




Figure S4. ^1H - ^1H COSY spectrum of compound 2 in $\text{DMSO}-d_6$. COSY, correlated spectroscopy; 2, nialamionsin; ppm, parts per million.




Figure S5. HSQC spectrum of compound 2 in DMSO- d_6 . HSQC, heteronuclear single quantum coherence; 2, nialamionsin; ppm, parts per million.




Figure S6. HMBC spectrum of compound 2 in DMSO- d_6 . HMBC, heteronuclear multiple bond correlation; 2, nialamionsin; ppm, parts per million.




Figure S7. NOESY spectrum of compound 2 in DMSO- d_6 . NOESY, nuclear Overhauser effect spectroscopy; 2, nialamionsin; ppm, parts per million.




Figure S8. HRESIMS spectrum of compound 2. HRESIMS, high-resolution electrospray ion mass spectrum; 2, nialamionsin; ppm, parts per million.




Figure S9. Full-length western blotting for iNOS and COX-2 of compounds 1 and 5 in LPS-stimulated RAW264.7 and DH82 cells iNOS, inducible NO synthase; COX, cyclooxygenase; LPS, lipopolysaccharide; 1, nialamide; 5, 3-hydroxy-*N*-benzylpropanamide.




Figure S10. Full-length western blotting for p-NF-κB and p-IκB of compounds 1 and 5 in LPS-stimulated RAW264.7 cell. p-, phosphorylated; 1, nialamide; 5, 3-hydroxy-*N*-benzylpropanamide; LPS, lipopolysaccharide.

